Novogen Limited - Product Pipeline Review - 2015

Date: November 30, 2015
Pages: 28
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NE559D865D4EN
Leaflet:

Download PDF Leaflet

Novogen Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Novogen Limited - Product Pipeline Review - 2015’, provides an overview of the Novogen Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novogen Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Novogen Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Novogen Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Novogen Limited’s pipeline products
Reasons to buy
  • Evaluate Novogen Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Novogen Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Novogen Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Novogen Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novogen Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Novogen Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Novogen Limited Snapshot
Novogen Limited Overview
Key Information
Key Facts
Novogen Limited - Research and Development Overview
Key Therapeutic Areas
Novogen Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Novogen Limited - Pipeline Products Glance
Novogen Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Novogen Limited - Drug Profiles
ATM-3507
Product Description
Mechanism of Action
R&D Progress
TR-100
Product Description
Mechanism of Action
R&D Progress
Trilexium
Product Description
Mechanism of Action
R&D Progress
TRXE-0025
Product Description
Mechanism of Action
R&D Progress
Small Molecules for CNS and Muscular Dystrophy Diseases
Product Description
Mechanism of Action
R&D Progress
Novogen Limited - Pipeline Analysis
Novogen Limited - Pipeline Products by Route of Administration
Novogen Limited - Pipeline Products by Molecule Type
Novogen Limited - Recent Pipeline Updates
Novogen Limited - Dormant Projects
Novogen Limited - Company Statement
Novogen Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Novogen Limited, Key Information
Novogen Limited, Key Facts
Novogen Limited - Pipeline by Indication, 2015
Novogen Limited - Pipeline by Stage of Development, 2015
Novogen Limited - Monotherapy Products in Pipeline, 2015
Novogen Limited - Partnered Products in Pipeline, 2015
Novogen Limited - Partnered Products/ Combination Treatment Modalities, 2015
Novogen Limited - Preclinical, 2015
Novogen Limited - Discovery, 2015
Novogen Limited - Pipeline by Route of Administration, 2015
Novogen Limited - Pipeline by Molecule Type, 2015
Novogen Limited - Recent Pipeline Updates, 2015
Novogen Limited - Dormant Developmental Projects,2015
Novogen Limited, Subsidiaries

LIST OF FIGURES

Novogen Limited - Pipeline by Top 10 Indication, 2015
Novogen Limited - Pipeline by Stage of Development, 2015
Novogen Limited - Monotherapy Products in Pipeline, 2015
Novogen Limited - Pipeline by Top 10 Molecule Type, 2015
Skip to top


Xention Limited - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 29 pages
Mesoblast Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 51 pages
Pharminox Limited - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 21 pages
Cellmid Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 30 pages
Immunocore Limited - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 33 pages

Ask Your Question

Novogen Limited - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: